Financial Performance Overview
Nath Bio-Genes reported strong financial results for FY26 with consolidated revenue growing 22% to ₹445.10 Cr and net profit increasing 7.9% to ₹41.63 Cr. On a standalone basis, revenue grew 19.12% to ₹431.60 Cr with PAT of ₹44.43 Cr. The company maintained a robust equity base of ₹68.05 Cr while inventory increased significantly by ₹112.53 Cr year-on-year to support future operations.
Operational Highlights
The company's agricultural activities remained core to its business, with seed production accounting for 91% of total revenue. The cotton-paddy portfolio contributed 58% of revenue, while the maize segment emerged as the fastest-growing business with 78% value growth. International expansion continued through the Uzbekistan joint venture (Nath Bio-Genes CA), which contributed approximately ₹15 Cr to consolidated revenue despite reporting losses.
AGM and Corporate Governance
The 33rd Annual General Meeting is scheduled for September 24, 2026 via video conference. Key agenda items include adoption of FY26 financial statements, declaration of final dividend of ₹2 per share (record date: September 11, 2026), re-appointment of directors including Mrs. Jeevanlata Kagliwal and independent director Mr. Hitesh Purohit, and revision of Managing Director Mr. Satish Kagliwal's remuneration from ₹66 lakh to ₹144 lakh per annum effective January 2026.
Auditor Emphasis and Compliance Matters
Auditors highlighted several emphasis matters including recovery of ₹6.01 Cr against provisioning of advances to farmers/growers from earlier years, pending confirmations on certain accounts, and unaudited financial statements from the Uzbekistan joint venture considered for consolidation. The company maintained compliance with SEBI regulations and Companies Act provisions, with no material orders from regulators impacting going concern status.
Segment Performance and Geographic Distribution
Agricultural activities generated ₹407.09 Cr in revenue (91% of total) while trading contributed ₹38.01 Cr (9%). Geographically, 98.8% of revenue came from India with only 1.2% from international operations. The company maintained strong relationships with related parties including loans to Nath Bio-Genes (Central Asia) LLC (₹18.05 Cr) and Emrald Seeds Pvt Ltd (₹6.45 Cr).
Corporate Structure and Capital
The company maintained its capital structure with paid-up equity capital of ₹19.00 Cr divided into 1,90,04,000 equity shares of ₹10 each. Promoter shareholding remained stable at 45.60%. The board composition includes Mr. Satish Kagliwal as Managing Director, supported by key managerial personnel Mr. Amol Gupta (CFO) and Mr. Dhiraj Rathi (Company Secretary).